High Throughput Screening

High Throughput Screening for Toxicity Testing 

The majority of high throughput screening is performed during early drug development. However, it is usually performed on transformed cell lines which provide low predictive ability when it come to later stages of the drug development pipeline. This means that results stemming from early stage high throughput screening may have little value for optimization and even preclinical testing.

In 2001 and again in 2003, HemoGenix applied for and received SBIR Phase I and Phase II grants, respectively, to develop a high throughput hematotoxicity screening platform using fresh, primary cells. This platform that is now called HALO®-Tox HT, is the only high throughput hematotoxicity screening platform commercially available for contract research today.

HALO®-Tox HT is quite different from when it was first developed for the SBIR grants. However, it is now used and trusted by more than half of the top 50 biopharmaceutical companies worldwide.

Since HALO®-Tox HT was developed, HemoGenix® has developed similar high throughput screening assays for different tissues and organs, including immune cells, hepatocytes, cardiomyocytes, renal cells, skin cells, intestinal cells and others.

All of these platforms use exactly the same signal detection readout, namely ATP bioluminescence, thereby allowing potential cytotoxicity to be ranked according to tissue or organ. This is also the basis for the HemoGenix® ComparaTOX™ Platform that can also be applied to different species and cell types. Such studies are performed in high throughput mode.

However, HemoGenix® has performed numerous studies where a large numbers of compounds are tested simultaneously using its high throughput screening platforms. Under these conditions, it is often the case that a Full Report is not necessart, but rather a shorter compilation of results with the raw data. For this reason, HemoGenix® provides a Rapid Tox Study Report that is far less expensive than a Full Report.

For more information on our high throughput screening capabilities, please navigate to "Our Workflow" page and view other pages on this website for toxicity testing. Additional information can be obtained by contacting HemoGenix® at contractresearch@hemogenix.com or call (719) 264-6250.